ADS

Astellas' isavuconazole receives QIDP designation from FDA for zygomycosis treatment

By

February 27, 2014
Spread the love

Astellas Pharma Global Development, Inc., a subsidiary of Tokyo-based Astellas Pharma Inc., announced today that the U.S. Food and Drug Administration designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive mucormycosis (also known as zygomycosis), a life-threatening invasive fungal infection caused by certain emerging molds. …read more    

By